PET scan test for CXCR4 in many relapsed cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This early study tests a new PET scan tracer (a radioactive imaging agent) that may light up a cell marker called CXCR4 in certain blood and solid tumor cancers. It may help doctors see where cancers are and how much CXCR4 they have, which could guide future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You have one of these: indolent or relapsed/refractory non-Hodgkin lymphoma, histiocytic cancers (LCH, ECD, and/or RDD), MGUS/SMM or multiple myeloma, or certain solid tumors (examples include lung cancer or meningioma)
- Your cancer must have measurable disease based on standard criteria (doctors will confirm this)
- You cannot be in kidney failure from chronic kidney disease (your eGFR must be 30 or higher)
- You must be able to tolerate the PET/scan procedure (for example, no severe claustrophobia)
- If you can become pregnant: you must have a negative pregnancy test before the scan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new imaging method called CXCR4 PET/CT that may help doctors better see and understand lymphomas (a type of blood cancer). It is for people who are newly diagnosed or suspected of having lymphoma and have already had a standard PET/CT.
This early-stage trial tests a new radioactive tracer called [68Ga]Ga-R54 that helps doctors see certain advanced cancers (like breast, lung, colon, ovary, pancreas, or multiple myeloma) on PET scans. The tracer targets a specific protein (CXCR4) found on cancer cells, which may help doctors better detect and understand your cancer.
This study tests a new imaging agent called 64Cu-LLP2A to see if it can better detect certain blood cancers like multiple myeloma and low-grade lymphomas. It aims to find tumors more clearly than standard scans, which could help your doctor plan the best care for you.
This trial looks at an imaging scan called CXCR4-targeted PET/CT to help doctors see certain blood cancers. You may be helped by getting clearer information about where cancer is in your body, and the results may guide future care.
This trial uses a special imaging scan (CXCR4 PET/CT) to help diagnose or evaluate certain diseases linked to a protein called CXCR4. It may offer more detailed information than standard scans.
This study tests a new PET scan method (using a special tracer called 18F-Pentixafor) to see if it can better find and track blood cancers. It may help your doctors get more detailed images with less radiation.
Hear when a new Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.